5-methyl-4-(thiazol-2-yldiazenyl)benzene-1,3-diol | 96627-61-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 5-methyl-4-(thiazol-2-yldiazenyl)benzene-1,3-diol
• CAS: 96627-61-1
• 化学式: C₁₀H₉N₃O₂S
• mdl: MFCD00011562
• 分子量: 235.266
• InChiKey: LABKTXRFMJIJAU-OUKQBFOZSA-N

物化性质

• 熔点：
  211-213 °C (dec.)(lit.)
• 沸点：
  441.7±53.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.63
• 重原子数：
  16.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  78.07
• 氢给体数：
  2.0
• 氢受体数：
  5.0

制备方法与用途

用途 

络合指示剂。

文献信息

• Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates
  申请人：Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch

  公开号：EP2368558A1

  公开（公告）日：2011-09-28

  The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates.

  本发明涉及适用作蛋白质错误折叠和/或蛋白质聚集调节剂的化合物。这些化合物特别适用作淀粉样聚集物形成的抑制剂和/或淀粉样表面特性的调节剂，和/或作为淀粉样聚集物的降解或减少的激活剂。
• Azophenols as ERG oncogene inhibitors
  申请人：The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

  公开号：US10238639B2

  公开（公告）日：2019-03-26

  Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.

  描述了野生型或改变的 ERG 蛋白表达的选择性偶氮苯酚抑制剂，其中抑制剂代表式 (I) 或式 (II) 的化合物 其中 X、X1、X2、X3、X4 和 X5、R1 至 R4 和 R9 如所述。
• AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES
  申请人：Max-Delbrück-Centrum für Molekulare Medizin

  公开号：EP2549999A1

  公开（公告）日：2013-01-30
• Azophenols as ERG Oncogene Inhibitors
  申请人：The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

  公开号：US20180169074A1

  公开（公告）日：2018-06-21

  Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X 1 , X 2 , X 3 , X 4 and X 5 , R 1 through R 4 and R 9 are as described.
• AZOPHENOLS AS ERG ONCOGENE INHIBITORS
  申请人：The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

  公开号：US20210299106A1

  公开（公告）日：2021-09-30

  Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X 1 , X 2 , X 3 , X 4 and X 5 , R 1 through R 4 and R 9 are as described.